ASX:RCE Recce Pharmaceuticals (RCE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Recce Pharmaceuticals Stock (ASX:RCE) 30 days 90 days 365 days Advanced Chart Get Recce Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume630,087 shsAverage VolumeN/AMarket CapitalizationA$104.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Recce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, the company engages in R327 Intravenous which provides serious/life-threatening bacterial infections, including sepsis which is in the phase 1 trial; urinary tract infections, including urosepsis; rapid infusions sepsis in the phase 2 trial; and R327 Topical offers wound infections, including infected burns; and diabetic foot ulcer infections in Phase 2 trails. Further, the company operates various pre-clinical programs, such as Mycobacterium abscessus which is in phase 1 clinical trial; bacterial sinusitis; and additional TBA. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia. Read More Receive RCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recce Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RCE Stock News HeadlinesRecce Pharmaceuticals Issues New Shares to Support Anti-Infective DevelopmentJuly 14, 2025 | tipranks.comRCE News, Analysis, Announcements & Results | Recce Pharmaceuticals Ltd | AFR - Financial ReviewJuly 2, 2025 | afr.comUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.July 18 at 2:00 AM | Stansberry Research (Ad)Recce locks in $30M to boost commercialisation across ASEAN regionJune 17, 2025 | msn.comFIL Limited Increases Stake in Recce PharmaceuticalsJune 11, 2025 | tipranks.comRecce Pharmaceuticals Strengthens Financial Position with Share Issue and Loan NegotiationsJune 10, 2025 | tipranks.comRecce Pharmaceuticals Expands Market Reach with New ASX Securities QuotationJune 9, 2025 | tipranks.comLong Shortz with Recce: $15 million capital raise for Phase 3 Indonesian and Australia trialsJune 6, 2025 | msn.comSee More Headlines RCE Stock Analysis - Frequently Asked Questions How were Recce Pharmaceuticals' earnings last quarter? Recce Pharmaceuticals Ltd (ASX:RCE) announced its earnings results on Wednesday, February, 27th. The company reported ($0.01) EPS for the quarter. Recce Pharmaceuticals had a positive trailing twelve-month return on equity of 392.94% and a negative net margin of 741.65%. What other stocks do shareholders of Recce Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Recce Pharmaceuticals investors own include ASE Technology (ASX), FlexiGroup Limited (FXL.AX) (FXL), Prima BioMed (IMMP), Mavenir (MVNR), Cronos Group (CRON), Cree (CREE) and Caladrius Biosciences (CLBS). Company Calendar Last Earnings2/27/2019Today7/18/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:RCE CIKN/A Webwww.recce.com.au Phone61 2 8075 4585FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$17.66 million Net Margins-741.65% Pretax MarginN/A Return on Equity392.94% Return on Assets-238.11% Debt Debt-to-Equity Ratio-8.52 Current Ratio0.34 Quick Ratio4.81 Sales & Book Value Annual SalesA$5.03 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow13.57 Book ValueA($0.05) per share Price / BookN/AMiscellaneous Outstanding Shares231,870,000Free FloatN/AMarket CapA$104.34 million OptionableNot Optionable Beta1.05 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (ASX:RCE) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recce Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Recce Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.